The global Aptamers market is estimated to be valued at US$ 6265.49 Mn in 2023 and is expected to exhibit a CAGR of 18.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Aptamers are short strands of nucleic acids that bind to a specific target such as protein, ligand, or toxin. They are useful as diagnostic and therapeutic agents due to their ability to bind with high affinity and specificity.
Market key trends:
Nucleic acid aptamers are generated through Systematic Evolution of Ligands by Exponential enrichment (SELEX) technique which allows developing aptamers against various targets. This segment holds the largest market share due to high adoption of aptamers in diagnostics, research, and clinical development. The other key trends include increasing R&D investments by players for developing novel aptamers against various diseases and development of artificial intelligence and machine learning techniques to generate aptamers in a cost effective and rapid manner.
SWOT Analysis
Strength: Aptamers have high specificity and affinity for targets. They can be chemically synthesized and have low risk of triggering an immune response.
Weakness: Development of aptamers is expensive and time-consuming process. They also have relatively short shelf life compared to monoclonal antibodies.
Opportunity: Growing applications of aptamers in diagnostics, therapeutics and other areas due to their advantages over antibodies. Increasing R&D investments by pharmaceutical companies in development of aptamer-based drugs and diagnostics.
Threats: Safety issues related to aptamers may slow down their clinical adoption. Established market position of existing medical technologies poses challenges for aptamer-based solutions.
Key Takeaways
The Global Aptamers Market Size is expected to witness high growth, exhibiting CAGR of 18.4% over the forecast period, due to increasing R&D investments by pharma companies and growing applications of aptamers.
Regional analysis
North America dominated the aptamers market in 2023 and is expected to maintain its lead over the forecast period. This is attributed to presence of key market players and growing demand for personalized medicines in the region. Asia Pacific is anticipated to be the fastest growing market during the forecast period driven by increasing government investments in healthcare and biotechnology sectors.
Key players
Key players operating in the aptamers market are Ophthotech Corporation, Aptamer Sciences, Inc., Novartis AG, NeoNeuro SAS, Aptagen LLC, Aptus Biotech S.L., AM Biotechnologies, LLC, Base Pair Biotechnologies, Vivonics Inc., CAGE Bio Inc., TAGCyx Biotechnologies Inc., AstraZeneca, GlyTech, Inc., GC Biopharma Corp., Achiko AG, Agilent Technologies, Inc., SomaLogic Operating Co., Inc., Amsbio, and IVERIC bio, Inc. Larger players are focusing on partnerships and acquisitions to expand their product portfolios.
